Migraine With Aura, Stroke
Conditions
Brief summary
In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.
Detailed description
Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.
Interventions
DRUGCilostazol
Single oral administration of active or placebo one week apart
DRUGPlacebo
Sponsors
Herlev Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Migraine with aura * Minimum of 2 attacks/year
Exclusion criteria
* Chronic tension type headache * Cardiac arrhythmias
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aura | 24 hours | Induction of aura reported by an aura diary for 24 hours post medication |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Migraine | 24 hours | Induction of headache resembling usual migraine attacks |
| Endothelial response | 3 hours | Measurement of endothelial response by Endopat2000 before and after administration of placebo and cilostazol |
Countries
Denmark
Outcome results
None listed